Login to Your Account



In The Clinic NEWS

Top-line data from a trial of HS-410 (vesigenurtacel-L), Heat Biologics Inc.'s experimental non-muscle invasive bladder cancer (NMIBC) vaccine, fell short of hitting its primary endpoint in a phase II study, robbing the Durham, N.C.-based company of a desired chance to seek an accelerate approval in phase III, but not of its hope for success, CEO and founder Jeff Wolf told BioWorld Today.

EFFICACY, TOO, IN CELGENE PACT

With efficacy data thus far sans toxicity, "our dose escalation continues," Bluebird Bio Inc.'s chief medical officer, David Davidson, told BioWorld Today as onlookers cheered early success with the anti-BCMA chimeric antigen receptor (CAR) T-cell candidate BB2121 for relapsed/refractory multiple myeloma (MM), in development with Celgene Corp.

After toxicology problems led RNAi specialist Arrowhead Pharmaceuticals Inc. to give up on its clinical pipeline that deploys the EX1 delivery method, worries turned to whether the subcutaneous platform might run into similar woes.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: